MCID: CNT033
MIFTS: 47

Central Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Cancer

MalaCards integrated aliases for Central Nervous System Cancer:

Name: Central Nervous System Cancer 12 54 15 17
Malignant Neoplasm of Central Nervous System 12
Neoplasm of the Central Nervous System 6
Neoplasm of Central Nervous System 12
Central Nervous System Neoplasms 44
Central Nervous System Neoplasm 17
Central Nervous System Tumors 12
Central Nervous System Tumor 12
Malignant Tumor of Cns 12
Cns Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3620
MeSH 44 D016543
NCIt 50 C4627 C9293
SNOMED-CT 67 126951006 93744007
ICD10 32 C72.9
UMLS 70 C0085136 C0348374

Summaries for Central Nervous System Cancer

Disease Ontology : 12 A nervous system cancer that is located in the central nervous system.

MalaCards based summary : Central Nervous System Cancer, also known as malignant neoplasm of central nervous system, is related to central nervous system benign neoplasm and central nervous system hematologic cancer. An important gene associated with Central Nervous System Cancer is SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), and among its related pathways/superpathways are MicroRNAs in cancer and Alzheimers Disease. The drugs Ciprofloxacin and Orange have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, brain and spinal cord.

Related Diseases for Central Nervous System Cancer

Diseases in the Nervous System Cancer family:

Central Nervous System Cancer

Diseases related to Central Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 483)
# Related Disease Score Top Affiliating Genes
1 central nervous system benign neoplasm 33.0 SERPINA3 MIR34A MIR125B1 KDM4C H2AC18
2 central nervous system hematologic cancer 32.9 MIR199A1 MIR124-1 KDM4C
3 meningioma, familial 32.5 SMARCB1 SERPINA3 MIR548B MIR34A H2AC18
4 brain cancer 32.5 SMARCB1 MIR9-1 KDM4C H2AC18
5 nervous system cancer 31.6 SERPINA3 MIR9-1 MIR548B MIR34A MIR222 MIR21
6 glioma 31.5 MIR34A MIR222 MIR21 MIR19A MIR17 MIR15B
7 anaplastic astrocytoma 31.2 SERPINA3 MIR196A1 MIR10A KDM4C H2AC18
8 leukemia, acute myeloid 31.1 SERPINA3 MIR9-1 MIR34A MIR222 MIR21 MIR199A1
9 leukemia, acute lymphoblastic 31.1 MIR9-1 MIR222 MIR21 MIR199A1 MIR196A1 MIR17
10 secretory meningioma 31.0 SMARCB1 SERPINA3
11 leukemia, chronic myeloid 31.0 MIR9-1 MIR19A MIR199A1 MIR196A1 MIR17 MIR125A
12 demyelinating disease 30.8 SERPINA3 MIR9-1 MIR155 MIR125A MIR124-1 H2AC18
13 rhabdoid cancer 30.8 SMARCB1 SERPINA3 KDM4C H2AC18
14 in situ carcinoma 30.8 SERPINA3 MIR548B MIR17 H2AC18
15 diffuse astrocytoma 30.8 SERPINA3 KDM4C H2AC18
16 esophageal cancer 30.7 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR145
17 medulloblastoma 30.7 SMARCB1 MIR9-1 MIR34A MIR19A MIR17 MIR125A
18 brain glioma 30.7 MIR34A MIR10A KDM4C
19 placenta disease 30.7 SERPINA3 MIR199A1 H2AC18
20 immune deficiency disease 30.7 SERPINA3 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1
21 renal cell carcinoma, nonpapillary 30.7 MIR9-1 MIR34A MIR21 MIR199A1 MIR196A1 MIR17
22 lymphoma, non-hodgkin, familial 30.7 SERPINA3 MIR9-1 MIR34A MIR222 MIR21 MIR199A1
23 leukemia, chronic lymphocytic 30.6 MIR9-1 MIR34A MIR21 MIR19A MIR199A1 MIR196A1
24 malignant astrocytoma 30.6 SERPINA3 MIR9-1 MIR548B MIR19A MIR199A1 MIR196A1
25 pancreatic cancer 30.6 SERPINA3 MIR34A MIR222 MIR21 MIR199A1 MIR196A1
26 lung cancer 30.5 SERPINA3 MIR9-1 MIR34A MIR222 MIR21 MIR19A
27 lymphoma, hodgkin, classic 30.5 MIR21 MIR155 KDM4C
28 mismatch repair cancer syndrome 1 11.3
29 glioma susceptibility 2 11.2
30 glioma susceptibility 9 11.2
31 subependymal giant cell astrocytoma 11.1
32 central nervous system primitive neuroectodermal neoplasm 11.1
33 central nervous system sarcoma 11.1
34 cranial nerve neoplasm 11.1
35 central nervous system germ cell tumor 11.1
36 central nervous system melanocytic neoplasm 11.1
37 central nervous system mesenchymal non-meningothelial tumor 11.1
38 spinal cancer 11.1
39 mature t-cell and nk-cell lymphoma 10.6 MIR199A1 MIR17 KDM4C H2AC18
40 fetal alcohol spectrum disorder 10.6 MIR9-1 KDM4C H2AC18
41 miyoshi muscular dystrophy 1 10.6 MIR34A MIR222 MIR21 MIR155
42 oropharynx cancer 10.6 SERPINA3 MIR9-1 MIR199A1 H2AC18
43 skeletal muscle cancer 10.6 SMARCB1 SERPINA3 MIR199A1 H2AC18
44 endocrine organ benign neoplasm 10.6 SERPINA3 MIR21 MIR199A1 KDM4C H2AC18
45 fetal alcohol syndrome 10.6 MIR9-1 KDM4C H2AC18
46 muscle cancer 10.6 SMARCB1 SERPINA3 MIR9-1 MIR199A1 MIR196A1 H2AC18
47 esophagus adenocarcinoma 10.6 MIR21 MIR199A1 MIR196A1 MIR145
48 cardiovascular organ benign neoplasm 10.6 SERPINA3 MIR10A KDM4C H2AC18
49 chromosomal deletion syndrome 10.6 MIR9-1 MIR19A MIR17 MIR15B KDM4C H2AC18
50 extrinsic cardiomyopathy 10.6 SERPINA3 MIR21 MIR199A1 MIR10A H2AC18

Graphical network of the top 20 diseases related to Central Nervous System Cancer:



Diseases related to Central Nervous System Cancer

Symptoms & Phenotypes for Central Nervous System Cancer

Drugs & Therapeutics for Central Nervous System Cancer

Drugs for Central Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 399)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
2 Orange Approved Phase 3
3
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
4
Ondansetron Approved Phase 3 99614-02-5 4595
5
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
6
Trioxsalen Approved Phase 3 3902-71-4 5585
7
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
8
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
9
Ofloxacin Approved Phase 3 82419-36-1 4583
10
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
11
Thioguanine Approved Phase 3 154-42-7 2723601
12
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
13
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
14
Molgramostim Investigational Phase 3 99283-10-0
15
Mitolactol Investigational Phase 3 10318-26-0
16 Clavulanic Acids Phase 3
17 Amoxicillin-Potassium Clavulanate Combination Phase 3
18 beta-Lactamase Inhibitors Phase 3
19 Liver Extracts Phase 3
20 Antiemetics Phase 3
21 Emetics Phase 3
22 Photosensitizing Agents Phase 3
23 Anesthetics, General Phase 3
24 Anesthetics Phase 3
25 Dihematoporphyrin Ether Phase 3
26 Cytochrome P-450 Enzyme Inhibitors Phase 3
27 Ether Phase 3
28 Anesthetics, Inhalation Phase 3
29 Hematoporphyrins Phase 3
30 Hematoporphyrin Derivative Phase 3
31 Dopamine Agents Phase 3
32 Neurotransmitter Agents Phase 3
33 Central Nervous System Stimulants Phase 3
34 Dopamine Uptake Inhibitors Phase 3
35 Dexmethylphenidate Hydrochloride Phase 3
36
Nedaplatin Approved, Investigational Phase 2 95734-82-0
37
Ranitidine Approved, Withdrawn Phase 1, Phase 2 66357-59-3, 66357-35-5, 82530-72-1 3001055
38
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 1, Phase 2 7487-88-9 24083
39
Chlorpheniramine Approved Phase 1, Phase 2 113-92-8, 132-22-9 2725
40
Furosemide Approved, Vet_approved Phase 1, Phase 2 54-31-9 3440
41
Ethanol Approved Phase 1, Phase 2 64-17-5 702
42
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
43
Fenofibrate Approved Phase 2 49562-28-9 3339
44
Aminolevulinic acid Approved Phase 2 106-60-5 137
45
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
46
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
47
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
48
Dactinomycin Approved, Investigational Phase 2 50-76-0 2019 457193
49
Hydroxyurea Approved Phase 2 127-07-1 3657
50
Tamoxifen Approved Phase 2 10540-29-1 2733526

Interventional clinical trials:

(show top 50) (show all 603)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
2 A Prospective Randomised Controlled Trial Of Hyperfractionated Versus Conventionally Fractionated Radiotherapy In Standard Risk Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
3 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
4 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
5 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
6 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
7 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
8 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
9 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
10 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
11 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
12 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
13 Trial of Chemotherapy Utilizing Carboplatin, Vincristine, Cyclophosphamide and Etoposide for the Treatment of Central Nervous System Primitive Neurectodermal Tumors of Childhood Completed NCT00003859 Phase 3 carboplatin;cyclophosphamide;etoposide;vincristine sulfate
14 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
15 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
16 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
17 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
18 A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
19 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
20 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
21 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
22 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
23 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
24 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
25 SIOP Intracranial Germ Cell Tumours Protocol Completed NCT00293358 Phase 3 carboplatin;cisplatin;etoposide phosphate;ifosfamide
26 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
27 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
28 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
29 A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children Completed NCT00716976 Phase 3 sodium thiosulfate
30 Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
31 Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA Completed NCT00002875 Phase 3 cisplatin;cyclophosphamide;lomustine;mesna;vincristine sulfate
32 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
33 Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma Completed NCT00085098 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide
34 A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System Recruiting NCT03579602 Phase 2, Phase 3 tozuleristide
35 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
36 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial. Active, not recruiting NCT00626990 Phase 3 temozolomide
37 Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas Active, not recruiting NCT00978458 Phase 3 temozolomide
38 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Active, not recruiting NCT00085202 Phase 3 cisplatin;cyclophosphamide;vincristine
39 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
40 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
41 Phase III Randomized Evaluation of 13-Cis-Retinoic Acid (cRA) Plus Procarbazine Versus Procarbazine Alone in the Treatment of Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
42 The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric CNS Tumors Unknown status NCT02050243 Phase 1, Phase 2 5ALA
43 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
44 A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
45 Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL) Unknown status NCT01735747 Phase 2 nedaplatin;vincristine;Temozolomide
46 Tandem High-Dose Chemotherapy (HDCT) With Peripheral-Blood Stem-Cell Rescue for Patients With Metastatic Germ-Cell Tumors Failing First-Line Treatment Unknown status NCT01172912 Phase 2 carboplatin;cisplatin;dexamethasone;etoposide;ifosfamide
47 Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00562419 Phase 2 CT-322;irinotecan hydrochloride
48 Phase I/II Multicentre Trial of Salvage Chemotherapy With Gem-TIP for Relapsed Germ Cell Cancer Unknown status NCT00551122 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;ifosfamide;paclitaxel
49 A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide With Radiotherapy in Diffuse Pontine Gliomas Unknown status NCT00514397 Phase 2 motexafin gadolinium;temozolomide
50 Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma Unknown status NCT01062399 Phase 1, Phase 2 concurrent RAD001 10 mg/day;concurrent temozolomide;concurrent RAD001 2.5 mg/day;concurrent RAD001 5 mg/day;post-radiation RAD001 10 mg/day;post-radiation temozolomide

Search NIH Clinical Center for Central Nervous System Cancer

Cochrane evidence based reviews: central nervous system neoplasms

Genetic Tests for Central Nervous System Cancer

Anatomical Context for Central Nervous System Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Cancer:

19
Central Nervous System

MalaCards organs/tissues related to Central Nervous System Cancer:

40
Brain, Spinal Cord, Eye, Bone, Pituitary, Thyroid, Heart

Publications for Central Nervous System Cancer

Articles related to Central Nervous System Cancer:

(show top 50) (show all 204)
# Title Authors PMID Year
1
Arylsulfatase A in serum from patients with cancer of various organs. 54 61
1687888 1991
2
[Arylsulfatase A--physico-chemical properties and the use of enzyme radioimmunoassay in medical diagnosis]. 61 54
1688265 1991
3
Optimizing ANFIS using simulated annealing algorithm for classification of microarray gene expression cancer data. 61
33543413 2021
4
A New Epigenetic Model to Stratify Glioma Patients According to Their Immunosuppressive State. 61
33807997 2021
5
Revived Attention for Adult Craniopharyngioma. 61
32750720 2021
6
Validated quantitative needs assessment differences in the management of children with central nervous system cancer between Brazil, an upper middle-income country, and the United States of America, a high income country. 61
33760367 2021
7
Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies. 61
33800593 2021
8
Work Personality, Core Self-evaluation and Perceived Career Barriers in Young Adult Central Nervous System Cancer Survivors. 61
32399851 2021
9
Biomaterials and 3D Bioprinting Strategies to Model Glioblastoma and the Blood-Brain Barrier. 61
33326131 2021
10
Case report of pulmonary metastasis in a male Wistar rat glioblastoma model. 61
33627949 2021
11
Potential Drug Prediction of Glioblastoma Based on Drug Perturbation-Induced Gene Expression Signatures. 61
33575336 2021
12
Impact of non-CNS childhood cancer on resting-state connectivity and its association with cognition. 61
33205895 2021
13
Computational Modeling of Neuropsychological Test Performance to Disentangle Impaired Cognitive Processes in Cancer Patients. 61
32239149 2021
14
Expression Profile Analysis Identifies a Novel Seven Immune-Related Gene Signature to Improve Prognosis Prediction of Glioblastoma. 61
33708242 2021
15
A rare diagnosis of an extraventricular neurocytoma. 61
33767892 2021
16
Evaluation of the lifetime brain/central nervous system cancer risk associated with childhood head CT scanning in Japan. 61
33320957 2020
17
Chemotherapy-induced grey matter abnormalities in cancer survivors: a voxel-wise neuroimaging meta-analysis. 61
33047236 2020
18
GammaTile®: Surgically targeted radiation therapy for glioblastomas. 61
32618209 2020
19
Cerebral pleomorphic xanthoastrocytoma mimicking inflammatory granuloma: Two case reports. 61
33031279 2020
20
High-throughput microRNA profile in adult and pediatric primary glioblastomas: the role of miR-10b-5p and miR-630 in the tumor aggressiveness. 61
32888124 2020
21
Gene regulation network analysis reveals core genes associated with survival in glioblastoma multiforme. 61
32696617 2020
22
[Diffuse Leptomeningeal Glioneuronal Tumor with Subarachnoid Hemorrhage:A Case Report]. 61
32938808 2020
23
Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa. 61
32459291 2020
24
Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art. 61
32867643 2020
25
Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy. 61
32146576 2020
26
DNA repair and cell synthesis proteins: immunohistochemical expression and correlation with recurrence-regrowth in meningiomas. 61
32617895 2020
27
Locoregionally Delivered CAR T Cells Are Effective in CNS Cancer Models. 61
32385074 2020
28
Internet-based cognitive rehabilitation for WORking Cancer survivors (i-WORC): study protocol of a randomized controlled trial. 61
32690067 2020
29
Multiclass magnetic resonance imaging brain tumor classification using artificial intelligence paradigm. 61
32658726 2020
30
Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. 61
32129445 2020
31
Nonpharmacological interventions for cancer-related cognitive impairment in adult cancer patients: A network meta-analysis. 61
32004776 2020
32
Case-control study of brain and other central nervous system cancer among workers at semiconductor and storage device manufacturing facilities. 61
32019845 2020
33
[A Case of Primary Intracranial Malignant Melanoma Mimicking a Traumatic Brain Contusion]. 61
32312936 2020
34
A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place. 61
32124043 2020
35
Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas. 61
31896490 2020
36
Donors With Central Nervous System Cancer: Proceed With Vigilance. 61
31596741 2020
37
Brain structure prior to non-central nervous system cancer diagnosis: A population-based cohort study. 61
33395962 2020
38
Risk of Being Born Preterm in Offspring of Cancer Survivors: A National Cohort Study. 61
32850432 2020
39
Epidemiology of cancer in Saudi Arabia thru 2010-2019: a systematic review with constrained meta-analysis. 61
32968686 2020
40
Distinguishing Glioblastoma Subtypes by Methylation Signatures. 61
33329750 2020
41
Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature. 61
32082673 2020
42
Development and Validation of a Prognostic Nomogram to Predict Cancer-Specific Survival in Adult Patients With Pineoblastoma. 61
32793463 2020
43
Bioactive naphthoquinone and anthrone derivatives from endophytic Micromonospora sp. NEAU-gq13. 61
30585513 2019
44
How to assess and manage cognitive impairment induced by treatments of non-central nervous system cancer. 61
31553925 2019
45
Iguratimod encapsulated PLGA-NPs improves therapeutic outcome in glioma, glioma stem-like cells and temozolomide resistant glioma cells. 61
31654739 2019
46
Bimodular Antiparallel G-Quadruplex Nanoconstruct with Antiproliferative Activity. 61
31597343 2019
47
PD-L1/PD-1 Axis in Glioblastoma Multiforme. 61
31661771 2019
48
Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options. 61
31049790 2019
49
Age, cancer site and gender associations with symptoms and problems in specialised palliative care: a large, nationwide, register-based study. 61
31563863 2019
50
Evidence for increased surveillance of executive functioning in adolescent and young adult survivors of childhood cancer. 61
30395335 2019

Variations for Central Nervous System Cancer

ClinVar genetic disease variations for Central Nervous System Cancer:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SMARCB1 NM_003073.5(SMARCB1):c.351dup (p.Thr118fs) Duplication Pathogenic 493002 rs1555876140 GRCh37: 22:24135858-24135859
GRCh38: 22:23793671-23793672

Expression for Central Nervous System Cancer

Search GEO for disease gene expression data for Central Nervous System Cancer.

Pathways for Central Nervous System Cancer

GO Terms for Central Nervous System Cancer

Cellular components related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 SERPINA3 MIR222 MIR21 MIR19A MIR199A1 MIR17
2 extracellular exosome GO:0070062 9.73 H2AC18 MIR124-1 MIR125A MIR125B1 MIR145 MIR155
3 extracellular vesicle GO:1903561 9.23 MIR34A MIR222 MIR21 MIR19A MIR17 MIR15B

Biological processes related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.04 MIR34A MIR21 MIR155 MIR125A KDM4C
2 negative regulation of gene expression GO:0010629 9.97 MIR155 MIR17 MIR21 MIR34A MIR125A MIR124-1
3 negative regulation of cell migration GO:0030336 9.88 MIR9-1 MIR34A MIR21 MIR145
4 cellular response to hypoxia GO:0071456 9.85 MIR34A MIR17 MIR155 MIR124-1
5 negative regulation of inflammatory response GO:0050728 9.85 MIR124-1 MIR145 MIR155 MIR15B MIR19A MIR222
6 gene silencing by miRNA GO:0035195 9.83 MIR10A MIR124-1 MIR125A MIR125B1 MIR145 MIR155
7 negative regulation of interleukin-6 production GO:0032715 9.81 MIR19A MIR155 MIR125A
8 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.78 MIR222 MIR21 MIR17
9 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.77 MIR199A1 MIR196A1 MIR155
10 negative regulation of blood vessel endothelial cell migration GO:0043537 9.76 MIR15B MIR155 MIR10A
11 negative regulation of angiogenesis GO:0016525 9.76 MIR10A MIR125A MIR125B1 MIR145 MIR15B MIR21
12 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.74 MIR222 MIR155 MIR125A
13 negative regulation of sprouting angiogenesis GO:1903671 9.73 MIR34A MIR19A MIR17
14 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.71 MIR222 MIR15B MIR155
15 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.71 MIR145 MIR199A1 MIR19A MIR21
16 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.69 MIR199A1 MIR17 MIR155
17 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.68 MIR34A MIR17
18 negative regulation of toll-like receptor signaling pathway GO:0034122 9.68 MIR19A MIR17
19 negative regulation of cell adhesion molecule production GO:0060354 9.67 MIR222 MIR155
20 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.67 MIR17 MIR155
21 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.67 MIR125B1 MIR125A
22 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.66 MIR19A MIR199A1
23 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.66 MIR21 MIR125A
24 negative regulation of matrix metallopeptidase secretion GO:1904465 9.65 MIR19A MIR199A1
25 negative regulation of microglial cell activation GO:1903979 9.65 MIR155 MIR124-1
26 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.65 MIR199A1 MIR17 MIR155
27 negative regulation of vascular endothelial growth factor production GO:1904046 9.65 MIR125A MIR15B MIR17 MIR199A1 MIR34A
28 negative regulation by host of viral genome replication GO:0044828 9.64 MIR222 MIR155
29 positive regulation of metalloendopeptidase activity GO:1904685 9.63 MIR21 MIR17
30 negative regulation of vascular wound healing GO:0061044 9.63 MIR34A MIR155
31 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.63 MIR125A MIR155 MIR222
32 negative regulation of STAT cascade GO:1904893 9.62 MIR125B1 MIR125A
33 negative regulation of regulatory T cell differentiation GO:0045590 9.62 MIR21 MIR155
34 positive regulation of connective tissue replacement GO:1905205 9.62 MIR155 MIR15B MIR199A1 MIR34A
35 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.61 MIR21 MIR17
36 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.61 MIR124-1 MIR125B1 MIR21
37 negative regulation of interleukin-21 production GO:0032705 9.59 MIR222 MIR21
38 negative regulation of interleukin-16 production GO:0032699 9.52 MIR145 MIR125A
39 miRNA mediated inhibition of translation GO:0035278 9.28 MIR124-1 MIR125B1 MIR145 MIR155 MIR15B MIR17

Molecular functions related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.56 MIR9-1 MIR34A MIR21 MIR17 MIR15B MIR145
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR9-1 MIR34A MIR222 MIR21 MIR19A MIR199A1

Sources for Central Nervous System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....